Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trialsArticle Published on 2020-04-292023-05-31 Journal: Human vaccines & immunotherapeutics [Category] Fulltext, 두창, 수두, 홍역, [키워드] adverse events doses healthcare professionals reactogenicity Recombinant herpes zoster vaccine [DOI] 10.1080/21645515.2020.1741312 PMC 바로가기
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19Review article Published on 2020-04-012022-10-05 Journal: Journal of Virus Eradication [Category] 신약개발, [키워드] accounted acute infection acute respiratory syndrome adjusted AEs analysis approved calculate Clinical studies Concentration conducted coronavirus coronavirus disease Course COVID-19 COVID-19 patient database demonstrated dosages dose doses drug drugs EC50 Effects Efficacy Endpoint Evidence for inclusion in vitro India ingredient inhibit initiated margin Metrics nitazoxanide pandemic participant per day pharmacies Placebo Placebo-controlled trials plasma concentration Potential treatment promote raised randomised controlled trial RCT RCTs Replication reported required Research Result review Safe safety profile SARS-CoV-2 searched Serious Adverse Event shown significant difference teratogenic teratogenicity treat Treatment treatments for COVID-19 Trial trials [DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article
Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case SeriesCOVID-19 치료를 위한 정맥 면역글로불린(Prevagen 또는 Octagam)의 사용: 후향적 사례 시리즈Observational Study Published on 2020-01-012022-09-11 Journal: Respiration [Category] MERS, 임상, 진단, 치료제, [키워드] acute respiratory distress acute respiratory distress syndrome administration Admission ARDS attenuate caused chronic Clinical course clinical courses clinical trial Comorbidity coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 infection COVID-19 patient D-dimer demonstrated disease distress dose dose administration doses elevated evaluated hospital discharge Hospital stay ICU Illness severity Immunoglobulin immunomodulators IMPROVE Inflammatory response Inflammatory responses Intravenous immunoglobulin intravenous immunoglobulin. IVIG Mann-Whitney U test mechanical ventilation median median age median time men moderate moderate to severe occurred Patient patients with moderate Physiology ranged reduce reduce mortality regimen resources respiratory distress Respiratory distress syndrome score Sery Severe COVID-19 Infection significantly shorter Stage survived syndrome thrombotic thrombotic event Thrombotic events Treatment utilization Ventilation women [DOI] 10.1159/000511376 PMC 바로가기 [Article Type] Observational Study
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialDNA 또는 NYVAC 벡터(HVTN 096)가 있는 외피 단백질을 포함하는 다가 HIV 백신의 안전성 및 면역원성: 1b상, 이중 맹검, 위약 대조 시험Article Published on 2019-10-072022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] active treatment Administered administration adverse event allergy antibodies antibody Antibody Response Antibody responses antibody-dependent cell-mediated cytotoxicity approach assigned binding binding antibody boost Cell-mediated cytotoxicity Combination component computer-generated Coverage cranial cytotoxicity died DNA dose doses double-blind early administration effective Efficacy enrolled envelope protein epitope finding followed by foundation funding glycoprotein gp120 healthy healthy volunteer healthy volunteers HIV infection HIV vaccine IgG IgG response IgG responses immunogenicity individual Infection Infectious diseases injection Lymphadenopathy marker measure Melinda Gate Melinda Gates motor vehicle Neutralising Antibodies outcome participant Participants Placebo placebo group placebo-controlled placebo-controlled trial Primary outcomes priming product Protein purified random Randomly reactogenicity regimen Registered responses risk Safety screened Serious Adverse Event Serious Adverse Events Switzerland the placebo group the vaccine trauma Treatment treatment group treatment groups Trial trials vaccination vaccination schedule Vaccinations Vaccine vector Volunteer [DOI] 10.1016/S2352-3018(19)30262-0 PMC 바로가기 [Article Type] Article
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study인간 면역 결핍 바이러스의 위험이 있는 젊은이들 사이에서 노출 전 예방에 대한 유지 및 준수를 촉진하기 위한 모바일 건강 중재의 무작위 대조 시험: EPIC 연구Articles and Commentaries Published on 2019-06-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] 95% CI 95% confidence interval acquisition adherence age bidirectional Blood clinical Concentration conducted Controlled demonstrated doses drug levels Effectiveness Efficacy enrolled EpiC evaluate evaluated HIV Human Human immunodeficiency virus immunodeficiency virus individual Infection insurance Intervention Latino Logistic men men who have sex with men (MSM) Mobile not differ Odds ratio outcome participant preexposure prophylaxis preexposure prophylaxis (PrEP) PrEP Prophylaxis Randomized Randomized controlled trial receive Registration reported Result retention risk robust Sex significantly significantly increased SOC Standard of care study visit tenofovir tenofovir diphosphate text-messaging TFV-DP Youth [DOI] 10.1093/cid/ciy810 PMC 바로가기 [Article Type] Articles and Commentaries
A dominant-negative mutant inhibits multiple prion variants through a common mechanism우성-음성 돌연변이는 공통 메커니즘을 통해 여러 프리온 변이체를 억제합니다Research Article Published on 2017-10-302022-09-06 Journal: PLoS Genetics [Category] Communicable Disease, [키워드] amyloid cells chaperone chaperones clearance conformation conformational conformations curing daughter cells determine determined by disorders dominant-negative dosage doses Effect fiber human disease inhibit inhibited inhibitor inhibitors interfere Intervention kinetic Lower mechanism mode molecular mutant observation overcome pathway persistence phenotype Phenotypes plasticity prion Protein protein conformations reported resulting sensitivity shown specificity stability unique variant variants [DOI] 10.1371/journal.pgen.1007085 PMC 바로가기 [Article Type] Research Article
Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial남아프리카 공화국의 유아 및 유아에 대한 비경구 P2-VP8-P[8] 서브유닛 로타바이러스 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조 시험Articles Published on 2017-05-052022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] 95% CI adjusted adverse event adverse events African approach assigned benefit block Block randomisation Cohort computer-generated different dose different doses dose dose-escalation doses double-blind eligible Endpoint enrolled finding FIVE followed by foundation Frequency funding geometric mean geometric mean titre geometric mean titres groups healthy highest HIV-uninfected homologous hospital IgA IgG IgG seroresponse immunogenic immunogenicity Infant Infants injection Injections Laboratory live oral rotavirus vaccines Local Melinda Gate Melinda Gates Mild neutralising antibody neutralising antibody seroresponse neutralising antibody seroresponses nine non-replicating rotavirus vaccine occurred offer oral rotavirus vaccine oral vaccines parent Parenteral parents participant Placebo placebo group placebo-controlled placebo-controlled trial primary immunogenicity randomisation randomised reaction receiving reduced Registered Research rotavirus rotavirus disease rotavirus vaccination rotavirus vaccine Safety safety analysis safety endpoint Serious Adverse Event Serious Adverse Events Serum IgA seroresponse Serum IgA seroresponses Seven severity South South Africa subunit Subunit vaccine systemic reaction systemic reactions the placebo group those receiving placebo Treatment Trial trivalent vaccination Vaccine was done was used [DOI] 10.1016/S1473-3099(17)30242-6 PMC 바로가기 [Article Type] Articles
A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal VaccinationResearch Article Published on 2009-01-132022-10-28 Journal: PLoS ONE [Category] Coronavirus, [키워드] Antigen Chinese dissemination doses Efficacy experiments generate genomic location Head-to-head comparison implication Inducing inoculated intramuscular intranasal Level maintain mice mucosal neutralizing antibody novel offer Prevent protective immune response response S gene SARS-CoV SARS-CoV neutralizing antibody spike glycoprotein Superior Tian vaccination Vaccine vaccine candidate vaccinia variant vector Viral transmission Viral vector was used wild-type [DOI] 10.1371/journal.pone.0004180 PMC 바로가기 [Article Type] Research Article